Abstract. Red Liriope platyphylla extract (EtRLP) has been used as an oriental medicine for treatment of several chronic conditions, such as neurodegenerative disorders, diabetes, and obesity. To investigate the laxative activity of EtRLP, the levels of key constipation markers and their molecular regulators were examined following administration of EtRLP in constipation Sprague Dawley (SD) rats treated with loperamide (Lop). Compared with the Lop+Vehicle-treated group, the excretion levels of urine and stool were significantly enhanced in the Lop+EtRLP-treated group, even though feeding levels were kept constant. There was a significant improvement in histological structure, cytological ultrastructure and mucin secretion in transverse colon sections from the Lop+EtRLP-treated group, compared with the Lop+Vehicle-treated group. The Lop+EtRLP-treated group exhibited a rapid recovery of the muscarinic acetylcholine receptor (mAChR) signaling pathway and of the endoplasmic reticulum (ER) stress response, compared with Lop+Vehicle-treated group. Spicatoside A, one of the key components detected in EtRLP, recovered the levels of inositol triphosphate (IP3) and $G\alpha$ in primary rat intestinal smooth muscle cells (pRISMCs). Taken together, the present results indicated that spicatoside A-containing EtRLP had therapeutic effects against Lop-induced constipation in SD rats via improvement of the mAChR downstream signaling pathway and the ER stress response.

Introduction

Chronic constipation, a gastrointestinal disorder, presents symptoms such as hard stools, infrequent bowel movements, incomplete bowel evacuation, difficulty during defecation, and the need for excessive straining (1-3). Often, this disorder is the result of insufficient dietary fiber and fluid intakes, decreased physical activity, colorectal cancer obstruction, hypothyroidism, and administration of certain drugs (4). Medical treatments for chronic constipation include the provision of bulk laxatives, osmotic agents, stimulant laxatives, lubricating agents, and neuromuscular agents (5,6). Commonly used stimulant laxatives include senna, bisacodyl and docusate; however, their use may be limited due to high costs and undesirable side effects including hypernatremia, hypokalemia and protein-losing enteropathy (7). Stimulant laxatives enhance the motility and secretion of the intestine through regulation of electrolyte transport by the intestinal mucosa, which occurs when smooth muscle, epithelial or nerve cells receive stimulation from such substances (8). Bisacodyl, a diphenylmethane derivative, has long been utilized as a first-line stimulant laxative worldwide. Bisacodyl is a prokinetic with hydrogogue effects that directly enhances motility, thereby enhancing the water content and decreasing transit time of stool in the large bowel (9,10).

Several plant extracts exhibit laxative activities via their ability to enhance intestinal motility, ileum tension, and the frequency and weight of stools. Leaf extracts of Aloe ferox Mill., agarwood (Aquilaria sinensis, A. crasna) and common fig (Ficus carica) paste are reported to significantly increase total stool weight and intestinal motility, and to normalize body weight in constipation rats treated with loperamide (Lop) (11-13). In addition, an aqueous extract of Liriope platyphylla (AEtLP) roots has been demonstrated to increase the frequency and weight of stools, villus length, crypt layer thickness, muscle thickness, mucin secretion, and accumulation of lipid droplets in crypt enterocytes (14). In that previous study, marked reductions in the levels of key

Correspondence to: Professor Daeyeon Hwang, Department of Biomaterials Science, College of Natural Resources and Life Science/ Life and Industry Convergence Research Institute, Pusan National University, 50 Cheonghak-ri, Miryang 627-706, Republic of Korea E-mail: dyhwang@pusan.ac.kr

Professor Jin Tae Hong, College of Pharmacy, Chungbok National University, 12 Gaeshin-Dong, Chungju 361-763, Republic of Korea E-mail: jinthong@chungbuk.ac.kr

Key words: constipation, red Liriope platyphylla, muscarinic acetylcholine receptors, endoplasmic reticulum stress, loperamide
factors in the muscarinic acetylcholine receptor (mAChR) signaling pathway were observed in the Lop+AEtLP-treated Sprague Dawley (SD) rats (14). Based on these findings, the present study investigated whether red *L. platyphylla* extract (EtRLP) has beneficial effects on factors associated with laxative effects in experimental constipation SD rats. The EtRLP used in the present study was produced by performing nine repetitions of a two-step process (steaming of *L. platyphylla* roots at 99°C for 3 h and air-drying at 70°C for 24 h). EtRLP has been considered a candidate for use in the improvement of constipation because it has been demonstrated to be useful in the treatment of various chronic conditions, including diabetes, obesity, and neurodegenerative disease (1-4). Additionally, although EtRLP is composed of crude protein, carbohydrates, crude ash, crude fat, and moisture, it has been reported to contain high concentration of total phenolic compounds, total flavonoids, and 5-hydroxymethyl-2-furfural (15,16). However, there are no reports on whether EtRLP has a therapeutic effect on constipation or on its mechanism of action.

In the present study, the laxative effects and molecular mechanism of EtRLP were investigated in constipation SD rats treated with Lop. The results provide evidence that EtRLP may be as effective as a commercial product containing bisacodyl, sennoside calcium, and docusate sodium at alleviating constipation. Additionally, the present study is the first to suggest that EtRLP's laxative effect may be correlated with control of the mAChR signaling pathway and the endoplasmic reticulum (ER) stress response. Finally, the role of spicatoside A, a key component in EtRLP, as a laxative compound was elucidated.

**Materials and methods**

**Preparation and analysis of EtRLP.** Fresh roots of *L. platyphylla* were kindly provided from the Miryang National Agricultural Cooperation Federation at Miryang, Korea, and then dried in a heating dryer (Ishinbiobase, Seoul, Korea) at 60°C after washing them clean. Voucher specimens of *L. platyphylla* roots (WPC-11-010) were deposited in the Functional Materials Bank of the Wellbeing RIS Center (FMB-WRIS Center) at Pusan National University. The root samples were confirmed to be *L. platyphylla* by Dr. Shin Woo Cha, Division of Herbal Crop Research, National Institute of Horticultural and Herbal Science (Eumseong, Korea).

EtRLP was prepared according to the method described previously (15). Briefly, a two-step process (steaming 200 g of dry root samples at 99°C for 3 h after air-drying at 70°C for 24 h) was repeated nine times to prepare *L. platyphylla* root powder (RLP) (Fig. 1A). Voucher specimens of RLP sample (WPC-11-015) were deposited in the FMB-WRIS Center at Pusan National University. Subsequently, the roots of RLP were completely reduced to powder by using an electric blender (Fig. 1B). A mixture of 200 g RLP root powder and 200 ml of distilled water was purified for 2 h at 100°C by using circulating extractor (IKA Labortechnik, Staufen, Germany). The supernatant of RLP was then concentrated in a vertical tube of rotary evaporator (EYELA, Tokyo, Japan) to obtain dry pellets of EtRLP, which were kept at -80°C until needed.

The composition and concentration of active compounds in the obtained EtRLP were analyzed by using methods described previously (15). The EtRLP was mainly comprised of large carbohydrates (83.22%) and small moisture (8.24%) with lesser amounts of proteins, fat, and ash. The total phenol and total flavonoid concentrations increased with an increasing number of steaming/drying episodes, but the level of crude saponins was saturated after five repetitions (Fig. 2). High-performance liquid chromatography (HPLC) results revealed that the levels of 5-hydroxymethyl-2-furfural were markedly increased with the increase in number of steaming/drying repetitions (Fig. 3); however, a reverse pattern was detected in the level of spicadoside A (Fig. 4).

**Animal experiments.** The experimental protocols involving the use of animals was reviewed and approved based on the ethical and scientific animal care procedures set by the Institutional Animal Care and Use Committee of Pusan National University (approval no. PNU-2012-0010). A total of 30 adult 8-week-old male SD rats (n=30) were purchased from Samtako BioKorea Com., (Osan, Korea) and handled in the Pusan National University, Laboratory Animal Resources Center, which is accredited by the Korea Food and Drug Administration (accredited unit no. 000231) and The Association for Assessment and Accreditation of Laboratory Animal Care International (accredited unit no. 001525). Rats were maintained in a pathogen-free state under a 12-h light/dark cycle (lights on between 06:00 h and 18:00 h) at a room temperature of 23±2°C and a relative humidity of 50±10%. Standard irradiated chow (Purina Mills, Seongnam, Korea) was provided *ad libitum*.

Constipation of SD rats was induced by subcutaneous injection of Lop (4 mg/kg body weight) in 0.9% NaCl twice a day for 3 days as described in previous studies (11), while the non-constipation rats received 0.9% NaCl alone. For the treatment experiments, 8-week-old SD rats (n=30) were divided into either non-constipation (n=14) or constipation (n=21) groups. The rats of non-constipation group were subdivided further into Non-treated (n=7) and EtRLP-treated (n=7) groups. The Non-treated group members were untreated throughout the experimental period, while the EtRLP-treated group members received a single treatment of 1,000 mg/kg body weight of EtRLP. SD rats of the Lop-induced constipation group were subdivided further into Lop+Vehicle-treated (n=7), Lop+EtRLP-treated (n=7), and Lop+Bisac-treated (n=7) groups. Following constipation induction, the Lop+Vehicle-treated group members received an equal amount of water via oral administration, whereas the other cotreatment group members received a single treatment of 1,000 mg/kg body weight of EtRLP. SD rats of the Lop-induced constipation group were subdivided further into Lop+Vehicle-treated (n=7), Lop+EtRLP-treated (n=7), and Lop+Bisac-treated (n=7) groups. Following constipation induction, the Lop+Vehicle-treated group members received an equal amount of water via oral administration, whereas the other cotreatment group members received a single treatment of 1,000 mg/kg body weight of EtRLP or 3.3 mg/kg body weight of Bisacodyl (Bisac). Primarily comprised of Bisac, sennoside calcium, and docusate sodium, the Bisac was purchased from Kolon Pharmaceuticals (Gyenggido, Korea). At 24 h following EtRLP treatment, all SD rats were euthanized by using compressed carbon dioxide (CO₂) gas. Tissue samples (transverse colon) were collected from animals and kept in Eppendorf tubes at ~80°C until use.

**Measurement of excretion parameters.** SD rats were maintained in metabolic cages during the experimental procedure to avoid excretion sample cross-contamination. Total excreted stools and urine were collected at 10:00 am every day following Lop or EtRLP treatment. Stool weight and number
were determined three times by using a chemical balance and a hand counter. Stool water content was defined as the weight of water in stools and calculated dry weight from wet weight as described in previous studies (11,14). Changes in urine volume were measured three times by using a volumetric cylinder.

**Western blot analysis.** Total tissue proteins were collected from the transverse colons of 5-6 rats from each of the five treatment groups (Non-, EtRLP-, Lop+Vehicle-, Lop+EtRLP- and Lop+BisaC-treated groups) and primary rat intestine smooth muscle cells (pRISMCs) using Pro-Prep Protein Extraction Solution (Intron Biotechnology Inc., Seongnam, Korea). The protein concentration of tissue lysates was calculated by bicinchoninic acid assay (cat. no. 23225; Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer’s instructions. Following the separation of total proteins (30 µg) by 4-20% SDS-PAGE, these proteins were then transferred to nitrocellulose membranes for 2-3 h at 40 V. Subsequently, the membranes were incubated with primary antibodies targeting mAChR M2 (cat. no. AMR-002; Alomone Labs, Jerusalem, Israel), mAChR M3 (1:1,000, cat. no. AMR-006; Alomone Labs), phosphoinositide 3-kinase (PI3K, 1:1,000, cat. no. 4292S; Cell Signaling Technology, Inc., Danvers, MA, USA), phosphorylated (p-) PI3K (1:1,000, cat. no. 4228S; Cell Signaling Technology, Inc.), protein kinase C (PKC, 1:1,000, cat. no. 2058S; Cell Signaling Technology, Inc.), p-PKC (1:1,000, cat. no. 9376S; Cell Signaling Technology, Inc.), inositol-requiring enzyme (IRE) 1α (1:1,000, cat. no. ab37073; Abcam, Cambridge, UK), IRE1β (1:1,000, cat. no. SC-10511; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), p-IRE1 (1:1,000, cat. no. 48187; Abcam), c-Jun N-terminal kinase (JNK, 1:1,000, cat. no. 9252; Cell Signaling Technology, Inc.), p-JNK (1:1,000, cat. no. 9251; Cell Signaling Technology, Inc.), guanine nucleotide binding protein (G) α (1:1,000, cat. no. ab128900; Abcam), eukaryotic initiation factor (eIF) 2α (1:1,000, cat. no. 9722; Cell Signaling Technology, Inc.), p-eIF2α (1:1,000, cat. no. 9721; Cell Signaling Technology, Inc.) or β-actin (1:3,000, cat. no. A5316; Sigma-Aldrich Co.; Merck KGaA, Darmstadt, Germany) overnight at 4°C. The membranes were then treated with washing buffer solution (137 mM NaCl, 10 mM Na₂HPO₄, 2 mM KH₂PO₄, 2.7 mM CAT).
KCl, and 0.05% Tween 20) and incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin (Ig) G antibody (1:1,000, cat. no. G21234; Invitrogen; Thermo Fisher Scientific, Inc.) at room temperature for 2 h. Finally, proteins on the membrane blot were detected with the Chemiluminescence Reagent Plus kit (Pfizer Inc., Gladstone, NJ, USA) and results were analyzed using SoftMax Pro 5.2 (Molecular devices, LLC, Sunnyvale, CA, USA).

**Histological analysis.** Briefly, transverse colon samples were collected from 5-6 SD rats from each of the five treatment groups and fixed with 10% formalin for 48 h. The fixed samples were then embedded in paraffin blocks, cut into 4 µm thick sections, and stained with hematoxylin and eosin (H&E) solution (Sigma-Aldrich Co.; Merck KGaA). Their morphological features, including villus length, crypt layer thickness, and muscle thickness were measured by using Leica Application Suite software (Leica Microsystems, GmbH, Wetzlar, Germany).

For detection of mAChR M2 and M3 via immunofluorescence staining analysis, transverse colon tissues were fixed in 10% formalin for 48 h, embedded in paraffin blocks, and sliced into 4 µm thick sections. Sections (n=5) were then deparaffinized with xylene, rehydrated with different concentrations of EtOH, and pretreated with blocking buffer containing 10% goat serum (cat. no. 94010; Vector Laboratories, Inc., Burlingame, CA, USA) in PBS solution for 30 min at room temperature. The pretreated sections were then incubated with anti-mAChR M2 (1:200, cat. no. AMR-002; Alomone Labs) or anti-mAChR M3 (1:200, cat. no. AMR-006; Alomone Labs) antibodies diluted 1:1,000 in blocking buffer. After thorough washing in PBS solution, the sections were incubated with goat fluorescein isothiocyanate (FITC)-labeled anti-rabbit IgG (1:200, cat. no. A11008; Invitrogen; Thermo Fisher Scientific, Inc.) for 45 min, washed thrice in PBS for 30 min each, and mounted with vector shield mounting medium. Finally, green fluorescence intensity on the tissue section of transverse colon were detected using a Motic AE31 Inverted Phase contrast Fluorescence Microscope (Motic Incorporated, Ltd., Causeway Bay, Hong Kong).

For mucin staining, transverse colon samples collected from 5-6 rats from each of the five treatment groups were fixed with 10% formalin solution for 48 h, embedded in paraffin blocks, and sectioned into slices with 4 µm thickness, which were subsequently deparaffinized with xylene and rehydrated.
with different concentrations of EtOH. The sections (n=5) were then washed with distilled water (dH₂O) and stained with alcian blue staining solution (IHC WORLD, Woodstock, MD, USA). Finally, blue dots indicated mucin levels were observed in the stained colon tissue sections using light microscopy (Leica Microsystems, GmbH; DM500).

Transmission electron microscopy (TEM) analysis. Transverse colon tissues collected from 5-6 rats from each of the five treatment groups were fixed in 2.5% glutaraldehyde solution, rinsed with PBS solution, dehydrated with ascending concentrations of EtOH solution, postfixed in 1% osmium tetroxide (OsO₄) for 1-2 h at room temperature, and embedded in Epon 812 media (Polysciences, Hirschberg an der Bergstrasse, Germany). Subsequently, ultra-thin sections of colon tissue (70 nm thick) were placed on holey formvar-carbon coated grids and then made the negative stain grids using uranyl acetate and lead citrate. Morphological features of tissues were examined by TEM (Hitachi, Ltd., Tokyo, Japan).

HPLC analysis. Spicatoside A in EtRLP was detected by using an Agilent 1100 HPLC system (Agilent Technologies, Inc., Santa Clara, CA, USA) comprised of an autosampler, a degasser, a diode array detector, an automatic thermostat column compartment, and a quaternary pump. For spicatoside A analysis, a Shiseido CAPCELL PAK C18 MG column (Shiseido, Tokyo, Japan; 150x4.6 mm inside diameter, 5 mm particle size) was used with the following eluents: (A) 0.025% formic acid in water and (B) acetonitrile. A gradient programmer was used to apply the following HPLC program: 0-7 min (B: 8-12%, C: 10%), 7-23 min (B: 18-60% C: 10%), 23-35 min (B: 60%, C: 10%), 35-45 min (B: 60-90%, C: 10%), and 45-60 min (B: 90%, C: 10%). During analysis, the flow rate was 0.8 ml/min and the column temperature was 30°C. Flow rate and pressure were maintained at 1.53 l/min and 35±2 pound per square inch (psi), respectively. The output signals were detected at 254 nm and recorded with Clarity chromatography software (DataApex, Prague, Czech Republic).

Treatment of pRISMCs with spicatoside A. The pRISMCs used in the present study were prepared using a method described in previous studies, with slight modification (17). After the euthanasia of infant rats (3 days old) using a chamber filled with CO₂ gas, their small intestines were collected from 1 cm below the pyloric ring to the cecum and excised along the mesenteric border. Gut luminal contents were removed from intestine by washing with calcium-free Hanks solution (5.36 mmol/l KCl, 125 mmol/l NaCl, 0.34 mmol/l NaOH, 0.44 mmol/l NaHCO₃, 10 mmol/l glucose, 2.9 mmol/l sucrose, and 11 mmol/l HEPES, pH 7.4). The opened intestine was pinned to the base plate of a silicon-covered Petri dish, and the mucosal layer was removed by sharp dissection. Small tissue strips of the circular and longitudinal muscles (~3-5 cm) were incubated in digestion mixture solution [1 mg/ml collagenase (Worthington Biochemical, Lakewood, NJ, USA), 0.5 mg/ml trypsin inhibitor (Sigma-Aldrich Co.; Merck KGaA), and 1 mg/ml bovine serum albumin (Sigma-Aldrich Co.; Merck KGaA)] at 37°C for 30 min. Digested tissue was centrifuged at 94 x g for 10 min and the pellet containing pRISMCs was harvested. The isolated cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM; Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) with 10% fetal bovine serum (FBS; Welgene, Daegu, Korea), then incubated in a culture incubator under a humidified atmosphere with 5% CO₂ and 95% air.

The spicatoside A, used as a key compound, was kindly provided by the National Development Institute of Korean Medicine (Daegu, Korea). To investigate the effects of spicatoside A, pRISMCs were seeded into culture dishes (100 mm diameter) at a density of 10⁶ cells in 10 ml, then incubated with 20 μM Lop for 12 h at 37°C. Subsequently, the culture media containing Lop were removed and the cells were incubated with 10 μM spicatoside A or PBS for a further 12 h, then collected by centrifugation at 848 x g for 10 min. The harvested pRISMCs were used to determine inositol triphosphate (IP3) concentration and to measure the expression levels of specific proteins.

Determination of IP3 concentration. IP3 levels in pRISMCs were measured by ELISA (Cusabio Biotech, Wuhan, China; CSB-E13004r), based on the manufacturer’s manual. The pRISMCs (2x10⁶) harvested from each of the five treatment groups were homogenized in ice-cold PBS (pH 7.2-7.4) by using a homogenizer (Sigma-Aldrich Co.; Merck KGaA). The supernatant from total cell lysate was collected for IP3 analysis. A specific antibody for IP3 was added to the supernatant and the mixture was incubated at 37°C for 1 h, followed by the addition of substrate solution at 37°C for 15 min. The reaction was terminated by the addition of stop solution into the plate, and the optical density was measured at 450 nm with a VERSA max plate reader (Molecular Devices, LLC, Sunnyvale, CA, USA).

Statistical analysis. Statistical analyses were performed with SPSS for Windows, release 10.10, standard version (SPSS, Inc., Chicago, IL, USA). One-way analysis of variance followed by Tukey’s post hoc test for multiple comparisons was performed to identify significant differences between groups. Data were presented as mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of EtRLP on feeding and excretion behavior of SD rats with Lop-induced constipation. To investigate whether EtRLP treatment affects the feeding and excretion behavior of SD rats with Lop-induced constipation, the daily food intake, daily water consumption, and daily stool excretion were determined in each of the three treatment groups. No significant difference was observed in body weight and daily food intake between the Lop+Vehicle-treated and Lop+EtRLP-treated groups, while daily water consumption in the Lop+EtRLP-treated group was at a similar level to the Non-treated group (Table I). In addition, the decreased stool numbers and urine volumes were recovered in the Lop+EtRLP- and Lop+Bisac-treated groups to similar levels to the Non-treated group. Indeed, the water content and weight of stool in the Lop+EtRLP-treated group were significantly higher compared with the Non-treated group (Table I). These results suggest that EtRLP treatment can improve the excretion parameters of SD rats with Lop-induced constipation.
Table I. Constipation parameters following EtRLP treatment in experimental rats.

| Category             | Non-treated | EtRLP     | Vehicle | EtRLP | Bisac     |
|----------------------|-------------|-----------|---------|-------|-----------|
| Body weight (g)      | 292.15±7.29 | 294.65±12.22 | 306.09±14.39 | 297.21±24.34 | 279.15±21.24 |
| Food intake (g/day)  | 29.07±4.38  | 28.05±3.72  | 28.94±3.46  | 28.42±3.67  | 27.13±3.81  |
| Water consumption (ml)| 21.80±2.49  | 23.00±2.00  | 27.40±1.94  | 23.00±2.23  | 24.00±3.80  |
| Stool number (ea)    | 41.00±7.80  | 46.00±6.50  | 32.00±5.30  | 50.00±5.20  | 47.00±6.80  |
| Stool weight (g)     | 4.33±0.58   | 4.43±0.50   | 2.17±0.29   | 4.5±0.50    | 4.17±0.76   |
| Water content (%)    | 49.30±2.12  | 77.7±2.72   | 27.62±1.58  | 74.04±3.33  | 68.78±2.4   |
| Urine volume (ml)    | 10.20±2.31  | 11.35±3.70  | 14.95±3.17  | 12.75±5.36  | 11.22±5.08  |

*P<0.05 compared with the non-treated group; **P<0.05 compared with the Lop+Vehicle-treated group. Lop, loperamide; EtRLP, Red *Liriope platyphylla* extract; Bisac, bisacodyl.

Figure 5. Histological structure of transverse colon collected from Lop-induced constipated rats. Following the collection of transverse colons from the Non-, EtRLP-, Lop+Vehicle-, Lop+EtRLP-, and Lop+Bisac-treated groups, H&E stained sections of these tissues were observed at two magnifications via light microscopy (left and middle column). Mucin on the tissue sections was stained with alcian blue (right column). Crypt layer thickness, muscle thickness, and villus length in transverse colon were measured in H&E stained images with the Leica Application Suite software. EtRLP, Red *Liriope platyphylla* extract; Lop, loperamide; Bisac, bisacodyl; H&E, hematoxylin and eosin.
Recovery effect of EtRLP on histological alterations of the transverse colon. To investigate the beneficial effects of EtRLP treatment on the recovery of constipation-affected histological structures of the transverse colon, we examined the villus length, thickness of crypt layer and muscle, and mucin secretion. We measured these parameters in the Non-treated group, following Lop+EtRLP or Lop+Bisac treatment. We observed that the villus length increased by 110-120% relative to the Lop+Vehicle-treated group (Fig. 5 and Table II). Furthermore, the alterations in crypt layer and muscle thickness were similar to those in villus length, although crypt layer thickness only increased by 30-35% relative to the Non-treated group. Following Lop+EtRLP or Lop+Bisac treatments, the villus length increased by 110-120% relative to the Lop+Vehicle-treated group (Fig. 5 and Table II).

Improvement effect of EtRLP treatment on transverse colon ultrastructure. To determine if the recovering effect of EtRLP on transverse colon histological structure is accompanied by significant changes in its ultrastructure, organelles and cell microstructures were evaluated by TEM analysis. In the Non-treated group, crypts of Lieberkuhn formed a round structure, in which goblet cells, enterocytes and paneth cells surrounded a central lumen. In the EtRLP-treated group, the crypt structure was very similar to that in the Non-treated group, even though the EtRLP-treated group had an increased number of lipid droplets. Following Lop treatment, the ultrastructure of the crypt changed markedly in various parts of the cell (Fig. 6). These results indicate that EtRLP treatment effectively restored Lop-altered transverse colon ultrastructure by enhancing the affluence of lipid droplets and granules in the crypts of Lieberkuhn in Lop-constipated rats.

Correlation between EtRLP treatment and the mAChR downstream signaling pathway. To determine if the laxative effects of EtRLP were accompanied by alterations in mAChRs signaling, the expression levels of mAChR-related proteins were detected in the three Lop-treated groups. We observed that EtRLP treatment improved the abnormal histological structure of the transverse colon in SD rats with Lop-induced constipation.

Effects of EtRLP on the ER stress response. To investigate the beneficial effects of EtRLP treatment on the ER stress response in SD rats with Lop-induced constipation, we examined related protein levels and ultrastructure of the transverse colon, as well as altered stress biomarkers, including lipids and granules enhanced notably in enterocytes and paneth cells, while the levels in goblet cells were constant. However, in the Lop+EtRLP- and Lop+Bisac-treated groups, lipid droplets and granules were not distributed in enterocytes and paneth cells (Fig. 6). These results indicate that EtRLP treatment effectively restored Lop-altered transverse colon ultrastructure by enhancing the affluence of lipid droplets and granules in the crypts of Lieberkuhn in Lop-constipated rats.

Table II. Histological parameters of experimental rats with Lop-induced constipation.

| Categories                        | Non-treated | EtRLP | Vehicle | EtRLP | Bisac |
|-----------------------------------|-------------|-------|---------|-------|-------|
| Mucosa thickness (µm)             | 257.5±34.4  | 264.3±25.1 | 167.9±18.3a | 219.2±11.1b | 225.3±9.8b |
| Muscle thickness (µm)             | 152.0±14.6  | 123.3±10.1 | 80.8±9.0  | 189.4±11.1b | 172.8±27.2b |
| Flat luminal surface thickness (µm)| 35.7±3.0   | 36.6±4.2 | 15.3±3.3  | 33.4±1.9b  | 31.7±1.7b  |
| Number of goblet cell (ea)        | 284.8±13.8  | 282.4±8.8 | 164.0±23.9a | 299.6±107b | 219.8±13.6b |
| Number of crypt of lieberkuhn (ea)| 33.8±3.7   | 26.4±5.7 | 11.2±1.9  | 22.2±2.4b  | 24.0±2.9b  |

aP<0.05 compared with the non-treated group; bP<0.05 compared with the Lop+Vehicle-treated group. Lop, loperamide; EtRLP, Red Liriope platyphylla extract; Bisac, bisacodyl.
Figure 6. Representative TEM images of rat transverse colons. Crypt ultrastructure of transverse colon in the (A) Non-treated, (B) EtRLP, (C) Lop+Vehicle, (D) Lop+EtRLP, and (E) Lop+Bisac-treated groups were observed by TEM at 1,800x magnification. (F) Crypt lumen diameter, (G) number of paneth cells, and (H) number of lipid droplets were determined with Leica Application Suite software. TEM analysis was performed in samples from five to six rats from each treatment group in triplicate. Data are presented as mean ± standard deviation from three replicates. *P<0.05 compared with the Non-treated group; #P<0.05 compared with the Lop+Vehicle-treated group. TEM, transmission electron microscopy; EtRLP, Red Liriope platyphylla extract; Lop, loperamide; Bisac, bisacodyl; Gb, goblet cells; Lm, crypt lumen; Gr, granule cells; Pn, paneth cells; Ld, lipid droplets.
Figure 7. Expression of key components in the mAChR signaling pathway. The expression levels of (A) mAChR M2, and (B) mAChR M3 and their respective downstream proteins were determined by (a-c) western blot and (d) immunofluorescence assays. Band intensities were evaluated relative to the intensity of the actin bands. Data are presented as mean ± standard deviation of three replicates (n=5-6 rats per treatment group). *P<0.05 compared with the Non-treated group; #P<0.05 compared with the Lop+Vehicle-treated group. mAChR, muscarinic acetylcholine receptor; EtRLP, Red Liriope platyphylla extract; Lop, loperamide; Bisac, bisacodyl; PI3K, phosphoinositide 3-kinase; PKC, protein kinase C; p-, phosphorylated.
or Lop+Bisac treatments, their levels almost recovered to the levels of the Non-treated group (Fig. 8A). Furthermore, the pattern of change in the phosphorylation levels of eIF2α was similar to the level changes in the phosphorylation of IRE1 in all treated groups. A similar phosphorylation pattern was also observed in JNK and IRE1 in the Non, Lop+Vehicle and Lop+EtRLP-treated groups. However, the level of JNK was not suppressed in Lop+Bisac-treated SD rats (Fig. 8A). Similar results were detected in the alteration patterns of ER stress protein levels detected by TEM analysis. We focused on alterations of paneth cells in the crypts of Lieberkühn because they have been associated with ER stress, through PERK, eIF2α, and ATF4 (18). Compared to the secretory granule decrease in the Lop+Vehicle group, the number of secretory granules was enhanced in the Lop+EtRLP-treated group, while that in the Lop+Bisac-treated group remained at a similarly low level as that in the Lop+Vehicle group. In addition, the ER membrane sack was closely stacked in the cytoplasm of paneth cells in the Lop+Vehicle-treated group, while an intact ER sack was observed in the Non-treated group. Following Lop+EtRLP or Lop+Bisac treatment, the ER structure was recovered to be similar to the Non-treated group; however, the changes were not as clear in the Lop+EtRLP-treated group as in the Lop+Bisac group (Fig. 8B). These results indicate that the Lop-induced ER stress response in paneth cells may be improved by EtRLP treatment.

Identification of spicatoside A as a key component. Spicatoside A was selected as a potential compound for the treatment of constipation, because it is a main compound of EtRLP, it can stimulate epithelial cells, and it has been linked to neuronal cell function. Briefly, we confirmed the existence of spicatoside A in EtRLP by performing HPLC. As illustrated in Fig. 9A, spicatoside A was detected in the HPLC chromatogram of EtRLP after a retention time of 32 min. Then, the effects of spicatoside A as a laxative compound were investigated. To accomplish this, alterations in the mAChR downstream signaling pathway were measured in pRISMCs cotreated with Lop and spicatoside A. The expression levels of Gq protein were increased by 165% in the Lop+Vehicle-treated group compared with the Non-treated group (Fig. 9B). However, the levels in the Lop+spicatoside A-treated group were similar to those in the Non-treated or the spicatoside A-treated groups (Fig. 9B). Next, the IP3 concentrations were examined. The increased levels of IP3 concentration in the Lop+Vehicle-treated group were significantly lower following spicatoside A treatment (Fig. 9C). The present results indicated that spicatoside A can be considered as a laxative and a potential candidate to improve the symptoms of chronic constipation.

Discussion

Recently, many herbal plants and medicinal foods have received research attention as novel therapeutic strategies for use in the treatment of chronic constipation and its related conditions, because they may effectively improve a variety of conditions without significant adverse side effects (12,15,19). In an effort to assess the effects of plant-derived drugs for the treatment of constipation, the present study conducted an efficacy study of EtRLP produced from L. platyphylla root via a steaming process on an experimental model of Lop-induced constipation. The results clearly demonstrated that EtRLP treatment had a laxative effect, leading to increased stool and urine volumes, recovery of histological and cell ultrastructure changes in colon, and enhanced mucus secretion. Furthermore, the results are the first to demonstrate that the laxative function of EtRLP is closely associated with regulation of the mACHr signaling pathway and the ER stress response in the transverse colon of SD rats.

Extracts of L. platyphylla and RLP roots contain a great variety of functional components, but elucidation of the correlation between their properties and therapeutic effects requires further analyses. Carbohydrates (6.89 g/100 g) and sodium (3.62 g/100 g) are the predominant components of dried roots of L. platyphylla, with proteins, fats, and sugars also present but at much lower levels, while the level of trans-fat, saturated fat, and cholesterol are not detected (20). Previously, AEtLP was reported to contain saponins (1.73%), oligosaccharides (6.54%), succinic acid (111.48 mg/100 g), hydroxyproline (1,290 µg/100 g), and potassium (151.35 µg/100 g) (21). In addition, an ethanolic extract of L. platyphylla was examined, leading to the purification of five novel compounds, (−)-hiriopein A/B, (+)-platyphyllarin A/B, and ethyltributanoate, along with 21 previously reported secondary metabolites (22). However, very few reports have described the composition and bioactive compounds of EtRLP, a steam-processed extract of the L. platyphylla root. Previous reports have identified the total phenolic compounds, total flavonoid compounds, and the presence of diosgenin and 5-hydroxymethyl-2-furfural in EtRLP (15,16). However, further studies are needed to compare the concentrations of bioactive components between L. platyphylla and EtRLP to identify the key components with therapeutic effects against specific diseases. L. platyphylla, the raw material from which EtRLP was derived, has also been reported to effectively improve the symptoms of Lop-induced constipation (14). However, the rate of improvement in key factors was greater in the EtRLP-treated group compared with the L. platyphylla-treated group. In that previous study (14), stool weight, water content, and lumen diameter were higher in the EtRLP-treated group than in the L. platyphylla-treated group; however, the numbers of stools and paneth cells were similar in both groups. Furthermore, differences in the level of water consumption and food intake were detected in both groups, although body weights were similar. In the present study, water consumption was significantly lower in the Lop+EtRLP-treated group compared with the Lop+Vehicle group and the Lop+Bisac-treated group. In addition, food intake remained at a constant level in these groups even though their levels were lower than the Non-treated group. Such differences between studies can be attributed to differences in composition and concentration of several compounds contained in the treatment materials.

The function of gut epithelial cell is regulated by mAChRs, which serve a role in the digestion process of foods and in absorption of nutrients, electrolytes and water, through acetylcholine action (23). Although mAChRs are expressed on neuronal and non-neuronal cells in the gastrointestinal system, subtype-specific expressions have not been fully described in the different tissues of rat intestine. Indeed, only
Figure 8. Detection of the ER stress response. (A) Expression levels of ER stress-related proteins IRE1α, IRE1β, p-IRE1, JNK, p-JNK, eIF2α and p-eIF2α were measured by western blot analysis. Band intensities were evaluated relative to the intensity of the actin bands. Data are presented as mean ± standard deviation from three replicates (N=5-6 rats per treatment group). *P<0.05 compared with the Non-treated group; #P<0.05 compared with the Lop+Vehicle-treated group. (B) Ultrastructure of the secretory vesicle and ER in paneth cells were evaluated by transmission electron microscopy at 4,000x magnification. ER, endoplasmic reticulum; IRE, inositol-requiring enzyme; JNK, c-Jun N-terminal kinase; eIF2α, eukaryotic initiation factor 2α; p-, phosphorylated; EtRLP, Red Liriope platyphylla extract; Lop, loperamide; BisaC, bisacodyl.
a few studies have investigated whether M1, M2, and M3 are expressed in the epithelial cells of the ileum, or examined M4 expression in colon nerve fibers (1,24,25). In the present study, mAChR M2 and M3 proteins were detected in the transverse colon, and Gα12 subunits and IP3 were measured in pRISMcs treated with Lop, spicatoside A, or their combination. The expression levels of Gα12 were detected by western blot analyses. Band intensities were evaluated relative to the intensity of the β-actin bands. (C) The IP3 concentration in pRISM total lysate was determined with an ELISA kit, detecting IP3 levels of 5-1,000 pg/ml. Data are presented as mean ± standard deviation of three replicates. *P<0.05 compared with the Non-treated group; †P<0.05 compared with the Lop+Vehicle-treated group. Gα12, guanine nucleotide binding protein α12; IP3, inositol triphosphate; EtRLP, Red Liriope platyphylla extract; pRISMcs, primary rat intestinal smooth muscle cells; Lop, loperamide; Spi-A, spicatoside A.

Figure 9. High-performance liquid chromatography analysis of spicatoside A and its effects on Gα12 expression and IP3 concentration. (A) Chromatogram of spicatoside A with standard solution and EtRLP under optimized conditions. (B) Total cell lysate was harvested from Lop-pretreated and/or spicatoside A-treated pRISMcs. The expression levels of Gα12 were detected by western blot analyses. Band intensities were evaluated relative to the intensity of the actin bands. (C) The IP3 concentration in pRISM total lysate was determined with an ELISA kit, detecting IP3 levels of 5-1,000 pg/ml. Data are presented as mean ± standard deviation of three replicates. *P<0.05 compared with the Non-treated group; †P<0.05 compared with the Lop+Vehicle-treated group. Gα12, guanine nucleotide binding protein α12; IP3, inositol triphosphate; EtRLP, Red Liriope platyphylla extract; pRISMcs, primary rat intestinal smooth muscle cells; Lop, loperamide; Spi-A, spicatoside A.

Acknowledgements

We thank the animal technician, Jin Hyang Hwang, for directing the care and management of animals at the Laboratory Animal Resources Center.
Funding

The present study was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education (grant nos. 2014R1A1A2058360 and 2017R1D1A3B03032631).

Availability of data and materials

The analyzed datasets generated during the present study are available from the corresponding author on reasonable request.

Authors’ contributions

JEK, JG, HSL and DYH participated in the design of the study, sample preparation, animal experiments and data analyses. JTH helped with data analysis and manuscript preparation. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All protocols involving animals were approved by the Pusan National University Institutional Animal Care and Use Committee (approval no. PNU-2012-0010).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Walia R, Mahajan L and Steffen R: Recent advances in chronic constipation. Curr Opin Pediatr 21: 661-666, 2009.
2. McCallum IJ, Ong S and Mercer-Jones M: Chronic constipation in adults. BMJ 338: b381, 2009.
3. Emmanuel AV, Jacki Quigley EM and Talley NJ: Pharmacological management of constipation. Neurogastroenterol Motil 21 (Suppl 2): S41-S54, 2009.
4. Leung FW: Endotopic factors of chronic constipation: Review of the scientific evidence. Dig Dis Sci 52: 313-316, 2007.
5. Siegel JD and DiPalma JA: Medical treatment of constipation. Clin Colon Rectal Surg 18: 76-80, 2005.
6. Portalatin M and Winstead N: Medical management of constipation. Eur J Gastroenterol Hepatol 8: 1207-1211, 1996.
7. Azizzur Rahman et al: Paneth cells as a site of origin for three cell types present in the transverse colon. Mol Med Rep 15: 247-253, 2018.
8. Schindbeck NE and Müller-Lissner SA: Decreased substance P levels in rectal biopsies from patients with slow transit constipation. Eur J Gastroenterol Hepatol 8: 1207-1211, 1996.
9. Ewe K: Effects of bisacodyl on intestinal electrolyte and water net transport and transit. Perfusion studies in men. Digestion 37: 187-197, 1987.
10. Kienzle-horn S, Vix JM, Schuijt C, Peil H, Jordan CC and Kamm MA: Efficacy and safety of bisacodyl in the acute treatment of constipation: A double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 23: 1479-1488, 2006.
11. Wintola OA, Sunmonu TO and Afolayan AJ: The effect of Aloe vera (L.) leaf aqueous extract in rats. BMc Gastroenterol 10: 95, 2010.
12. Schiller LR: Review article: The therapy of constipation. Aliment Pharmacol Ther 15: 749-763, 2001.
13. Lee SY, Kim SY, Hong SH, Lee JS, Kim SH, Choi SI, Hwang IS, Lee YJ, Son HJ, Soon HJ and Hwang DY: Effects of five candidate laxatives derived from Liriope platyphylla on the 5-HT receptor signaling pathway in mice. Biosci Biotechnol Biochem 74: 1550-1555, 2010.
14. Lee SY, Kim SY, Hong SH, Lee JS, Kim SH, Choi SI, Hwang IS, Lee YJ, Son HJ, Lee SY, Hwang DY: Red Liriope tuber production by steam and drying process of Liriope tuber. BMc Gastroenterol 10: 95, 2010.
15. Lee SY, Kim SY, Hong SH, Lee JS, Kim SH, Choi SI, Hwang IS, Lee YJ, Son HJ, Lee SY, Hwang DY: Red Liriope tuber production by steam and drying process of Liriope tuber. BMc Gastroenterol 10: 95, 2010.
16. Ewe K: Effects of bisacodyl on intestinal electrolyte and water net transport and transit. Perfusion studies in men. Digestion 37: 187-197, 1987.
17. Kienzle-horn S, Vix JM, Schuijt C, Peil H, Jordan CC and Kamm MA: Efficacy and safety of bisacodyl in the acute treatment of constipation: A double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 23: 1479-1488, 2006.
18. Wintola OA, Sunmonu TO and Afolayan AJ: The effect of Aloe vera (L.) leaf aqueous extract in rats. BMc Gastroenterol 10: 95, 2010.
19. Ewe K: Effects of bisacodyl on intestinal electrolyte and water net transport and transit. Perfusion studies in men. Digestion 37: 187-197, 1987.
20. Kienzle-horn S, Vix JM, Schuijt C, Peil H, Jordan CC and Kamm MA: Efficacy and safety of bisacodyl in the acute treatment of constipation: A double-blind, randomized, placebo-controlled study. Aliment Pharmacol Ther 23: 1479-1488, 2006.
21. Wingate D, Phillips SF, Lewis SJ, Malagelada JR, Speelman P, Steffen R and Tytgat GN: Guidelines for adults on self-medication for the treatment of chronic diarrhea. Aliment Pharmacol Ther 15: 773-782, 2001.
22. Huigeheer SA, Awouters F and Tytgat GN: Riociguat treatment of loperamide-induced constipation. Br J Pharmacol 149: 463-479, 2006.
23. Levey AI: Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 52: 441-448, 1993.
24. Anini Y, Hansota T and Brubaker PL: Muscarinic receptors control postprandial release of glucagon-like peptide-1. In vivo and in vitro studies in rats. Endocrinology 143: 2420-2426, 2002.
25. Isler JA, Skalea AH and Alwina JC: Human cytomegalovirus infection activates and regulates the unfolded protein response. J Virol 79: 6809-6899, 2005.
26. Mattson MP: Calcium and neurodegeneration. Aging Cell 6: 337-350, 2007.
27. Chen YM, Zhou Y, Go G, Marmerstein JT, Kikkawa Y and Miner JH: Laminin β2 gene missense mutation produces endoplasmic reticulum stress in podocytes. J Am Soc Nephrol 24: 2229-2233, 2013.
28. Deldicque L, Cáñez PD, Philip A, Raymakers JM, Meakin PJ, Ashford ML, Delzene NM, Francaux M and Baar K: The unfolded protein response is activated in skeletal muscle by high-fat feeding: Potential role in the down regulation of protein synthesis. Am J Physiol Endocrinol Metab 299: E695-E705, 2010.
29. Zhou XK and Kaufman RJ: From endoplasmic-reticulum-reticulum stress to the inflammatory response. Nature 454: 455-462, 2008.
30. Ron D and Walter P: Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8: 519-529, 2007.
31. Schröder M and Kaufman RJ: The mammalian unfolded protein response. Annu Rev Biochem 74: 739-789, 2005.
32. Jiang Y, Zhang Y, Wark L, Ortiz E, Lim S, He H, Wang W, Medeiros D and Lin D: Wolfberry water soluble phytochemicals down-regulate ER stress biomarkers and modulate multiple signaling pathways leading to inhibition of proliferation and induction of apoptosis in Jurkat cells. J Nutr Food Sci: S2, pii: 001, 2011.
33. Xu C, Bailly-Maitre B and Reed JC: Endoplasmic reticulum stress: Cell life and death decisions. J Clin Invest 115: 2656-2664, 2005.
34. Yoshida H: ER stress and diseases. FEBS J 274: 630-658, 2007.
35. Niederreiter L and Kascer A: Endoplasmic reticulum stress and inflammatory bowel disease. Acta Gastroenterol Belg 74: 330-333, 2011.
36. Zheng J, Wu LJ, Zheng L, Wu B and Song AH: Two new monoterpene glycosides from Mentha spicata L. J Asian Nat Prod Res 5: 69-73, 2003.
37. Hur J, Lee P, Moon E, Kang I, Kim SH, Oh MS and Kim SY: Neurite outgrowth induced by spicatoic acid A, a steroidal saponin, via the tyrosine kinase A receptor pathway. Eur J Pharmacol 620: 9-15, 2009.
38. Park SH, Lee HJ, Ryu J, Son KH, Kwon SY, Lee SK, Kim YS, Hong HJ, Seok JH and Lee CJ: Effects of ophiogonin D and spicatoic A derived from Liriope tuber on secretion and production of mucin from airway epithelial cells. Phytomedicine 21: 176-176, 2014.
39. Lim H, Min DS, Kang Y, Kim HW, Son KH and Kim HP: Inhibition of matrix metalloproteinase-13 expression in IL-1β-treated articular chondrocytes by a steroidal saponin, spicatoic A, and its cellular mechanisms of action. Arch Pharm Res 38: 1108-1116, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.